Axsome Therapeutics Announces Results of MINDSET Physician Survey

Axsome Therapeutics (NASDAQ:AXSM) has announced results of the “Migraine Treatment Needs and Physician Receptivity” (MINDSET) survey.

As quoted in the press release:

MINDSET surveyed 106 neurologists and other migraine-treating physicians, who collectively treat more than 50,000 migraine patients annually, to understand physicians’ views of the unmet needs in the acute treatment of migraine and their potential receptivity to AXS-07. AXS-07 (MoSEIC™ meloxicam/rizatriptan) is a novel, oral, investigational medicine with distinct dual mechanisms of action, currently being evaluated in two Phase 3 efficacy trials (MOMENTUM and INTERCEPT) for the acute treatment of migraine.

According to the vast majority of physicians (85%), the most significant unmet need in the acute treatment of migraine is efficacy, and the majority of their patients who switch acute migraine treatments (62%) do so because of suboptimal efficacy. Physicians would prescribe AXS-07 to 37% of their patients who experience difficult-to-treat migraine if it demonstrates efficacy over placebo in the ongoing MOMENTUM trial in patients with a history of inadequate response. If AXS-07 demonstrates superior efficacy to rizatriptan as assessed in the MOMENTUM trial, approximately 90% of physicians report they are more likely to prescribe AXS-07 over currently available treatments, and over other emerging therapies, including oral CGRPs, that have not demonstrated superiority to current therapies. More than half (56%) of physicians report that they are significantly or moderately more likely to prescribe AXS-07 over these other treatments. Results of the survey also indicate that treating physicians are significantly concerned that suboptimal response to acute migraine treatments may lead to progression to chronic migraine. Furthermore, the majority of physicians believe it is very important to administer acute treatments at the earliest sign of migraine pain.

“Migraine causes people to lose their jobs, lose their relationships and lose their self-identify,” said Herriot Tabuteau, M.D., Chief Executive Officer of Axsome. “Results of the MINDSET survey of migraine-treating physicians highlight the significant need for more effective acute treatments for this debilitating neurological disease, and the desire of physicians for new treatments that demonstrate improvement over the current standard of care. The survey results therefore support the design of the ongoing MOMENTUM Phase 3 trial of AXS-07, which is being conducted in patients with a history of inadequate response to prior acute treatments, and which incorporates the very potent active comparator rizatriptan.

Click here to read the full press release.